Array BioPharma to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference

BOULDER, Colo., May 9, 2019

Event:	Bank of America Merrill Lynch 2019 Health Care Conference
Presenter:	Ron Squarer, Chief Executive Officer, Array BioPharma
Date:	Thursday, May 16, 2019 ARIVA.DE Börsen-Geflüster Kurse Array BioPharma -   0,00%
Time:	10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time
Webcast:	http://www.veracast.com/webcasts/baml/healthcare2019/id83306305205.cfm

About Array BioPharma
Array BioPharma Inc. is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets BRAFTOVI^® (encorafenib) capsules in combination with MEKTOVI^® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF^V600E or BRAF^V600K mutation in the United States and with partners in other major worldwide markets. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant metastatic colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), LOXO-292 (partnered with Eli Lilly), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Vitrakvi^® (larotrectinib, partnered with Bayer AG) is approved in the United States and Ganovo^® (danoprevir, partnered with Roche) is approved in China. For more information on Array, please visit www.arraybiopharma.com or follow @arraybiopharma on Twitter and LinkedIn.

BRAFTOVI^® and MEKTOVI^® are registered trademarks of Array BioPharma Inc. in the United States and various other countries. Erbitux^® is a registered trademark of Eli Lilly and Company. Vitrakvi^® is a registered trademark of Bayer AG. All trademarks are properties of their respective owners.

CONTACT:

Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate Communications
(303) 381-6600
ir@arraybiopharma.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-bank-of-america-merrill-lynch-2019-healthcare-conference-300847448.html

SOURCE Array BioPharma Inc.